Former Merck staffer charged in insider trading case

The latest pharma company to wind up in the middle of insider trading charges? Merck. A former employee at the drug giant has been charged after allegedly tipping off a former classmate about potential deals that scored him $683,000.

The SEC and federal prosecutors earlier this week filed a civil and criminal complaint against 32-year-old Zachary Zwerko, a senior finance analyst in the company's financial evaluation and analysis group, who worked at Merck ($MRK) until July, the Boston Globe reports. According to court documents seen by the paper, Zwerko shared info from confidential files about Merck's acquisition targets with his friend, a trader, who was not charged in this case.

From there, the friend went on to trade based on Zwerko's tips, making moves on a future Merck buyout of Idenix ($IDIX) as well as Ardea Biosciences and ViroPharma--both considered potential acquisitions at the time and both that were bid on by other companies, Reuters reports. The resulting charge? One count of conspiracy to commit securities fraud.

As a Merck spokeswoman told the news service, the company is cooperating with the SEC on the case. As for Zwerko, he's required to appear in a New York court this week after being released on a $1 million bond.

M&A, which has abounded in the pharma industry as of late, also set the stage for another recent insider trading charge--this one pinned on a former Bristol-Myers Squibb ($BMY) exec. Last October, Robert Ramnarine landed behind bars for a year and a day after pleading guilty to profiting off private information about BMS' buyout of diabetes-drug specialist Amylin Pharmaceuticals.

- see the Boston Globe story
- get more from Reuters

Special Report: The top 10 pharma companies by 2013 revenue - Merck | Pharma's top 10 M&A deals of 2013

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.